| Year |
Citation |
Score |
| 2017 |
Nayar U, Sadek J, Reichel J, Hernandez-Hopkins D, Akar G, Barelli PJ, Sahai MA, Zhou H, Totonchy J, Jayabalan D, Niesvizky R, Guasparri I, Hassane D, Liu Y, Sei S, et al. Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies. The Journal of Clinical Investigation. PMID 28504647 DOI: 10.1172/Jci83936 |
0.398 |
|
| 2017 |
Kelly JM, Amor-Coarasa A, Nikolopoulou A, Wüstemann T, Barelli P, Kim D, Williams C, Zheng X, Bi C, Hu B, Warren JD, Hage DS, DiMagno SG, Babich JW. Double Targeting Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 28450562 DOI: 10.2967/Jnumed.116.188722 |
0.312 |
|
| 2015 |
Nayar U, Sadek J, Reichel JB, Bunn D, Hernandez-Hopkins D, Barelli P, Sahai M, Totonchy J, Shizuko S, Shoemaker R, Warren D, Elemento O, Kaye K, Cesarman E. Exquisite Sensitivity of Plasma Cell Malignancies to a Novel Nucleoside Analog Is Mediated By Overexpressed Adenosine Kinase Blood. 126: 1812-1812. DOI: 10.1182/Blood.V126.23.1812.1812 |
0.486 |
|
| 2015 |
Nayar U, Reichel J, Sadek J, Hernandez-Hopkins D, Akar G, Zhou H, Sahai MA, Barelli P, Guasparri I, Totonchy J, Hassane D, Sei S, Shoemaker RH, Warren JD, Elemento O, et al. Abstract 4496: Genomics-based resistome analysis revealed endogenous adenosine kinase levels as a chief determinant of specificity for a novel nucleoside analog lymphoma inhibitor Cancer Research. 75: 4496-4496. DOI: 10.1158/1538-7445.Am2015-4496 |
0.309 |
|
| Show low-probability matches. |